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Developing nutritional component chrysin as a therapeutic agent:
Bioavailability and pharmacokinetics consideration, and
ADME mechanisms
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Chrysin is a promising naturally occurring flavonoid mainly found in honey and propolis. Although chrysin’s
biological activities have been demonstrated and the mechanism of actions has been determined using in vitro
and in vivo models, results from the current clinical studies were largely negative. A potential reason for
chrysin’s low efficacy in humans is poor oral bioavailability. In this paper, we reviewed the preclinical and
clinical pharmacokinetics studies of chrysin and analyzed the mechanism of poor in vivo efficacy with emphasis
on its bioavailability and ADME mechanism. Low aqueous solubility, rapid metabolism mediated by UGTs and
SULT, efficient excretion through efflux transporters including BCRP and MRP2 are the major reasons causing
poor systemic bioavailability for chrysin. However, because of efficient enterohepatic recycling facilitated by
phase II metabolism and efflux, chrysin’s bioavailability in the low GI tract is high. Thus, chrysin can be ideal for
treating diseases in the terminal ileum and colon (e.g., carcinoma, local infection) since it is localized in the
lower GI tract with limited delivery to other organs.

1. Introduction
Chrysin (5,7-dihydroxy-flavone, Fig. 1), a natural occurring flavo
noid found in diets (e.g., honey, propolis) possessing different pharma
cological functions, has attracted increasing interest in the last few
decades. The very first paper reporting chrysin in literature is back to
1893, where chrysin was isolated as a natural product and the structure
was elucidated [1]. After that, many papers have been published on
chrysin’s pharmacological efficacy, therapeutic properties, molecular
mechanism, and dispositions. Chrysin’s pharmacological efficacy has
been paid great attention to since the 1980s. A recent literature search
using “Chrysin” as the keyword in PubMed resulted in 1242 hits in the
last two decades (2000–2020), including 7 clinical studies papers, sug
gesting that chrysin is a promising compound in drug development.
One of the major natural sources of chrysin is honey and propolis.
The content of chrysin in honey could be up to 5.3 mg/kg [2]. Nowa
days, extracts containing high concentration of chrysin such as propolis
and honey, give rise to great interest to pharmacologists. Chrysin is also
found in vegetables, fruits and mushrooms [3], passion flowers, and
other herbal materials as one of the bioactive components [4]. In
addition to the aglycone, chrysin also exists in nature as O-glycoside or

C-glycoside forms. For example, chrysin-8-C-glucoside was identified in
different types of cherries including Prunus cerasus and Prunus avium)
[5]. Other examples include chrysin-7-O-glucoside from Moringa oleifera
[6] and Podocytisus caramanicus [7], and chrysin-6-C-glucoside from
passion flower Passiflora caerulea [8].
Chemically, chrysin belongs to the class of flavones containing two
benzene rings (i.e., A and B ring) and a six-member heterocyclic ring (i.
e., C ring). Unlike other flavonoids, chrysin only has hydroxyl groups on
the A ring (5,7-dihydroxyl) with no substituents on the B ring. This
unique substitutive feature makes it a suitable model compound in
structure-activity relationship studies. It is generally believed that
chrysin’s pharmacological efficacy is associated with moieties on the A
ring and C rings, where the hydroxyl can exert antitoxic effects [2].
Theoretically, the carbonyl conjugated with the double bond at positions
2 and 3 could form a PAIN-(pan-assay interference compounds)-like
moiety that may potentially cause certain toxicity [9]. However,
chrysin is relatively safe as proven in preclinical models. A daily con
sumption of 0.5–3.0 g of chrysin is considered safe in humans [10].
In vitro and in vivo studies have demonstrated chrysin’s beneficial
effect including neuroprotective [11], hepatoprotective [12], car
dioprotective [13], nephroprotective [12], anti-inflammatory [14],
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Fig. 1. Chrysin metabolic pathways.

the challenges in developing chrysin as a therapeutic drug. We also
provide several suggestions based on the biopharmaceutical
consideration.

Table 1
Summary of chrysin clinical studies.
#

Endpoints

Mechanism

Dose

Dosage
form

Ref

1

Alleviating
irinotecan-induced
late onsite diarrhea

UGT1A1
induction

Oral

[21]

2

Disposition
Prevent formation of
estrogens and
dihydrotestosterone

Aromatase
inhibitor

Oral
capsules
Oral
capsules

[25]

3

4

Prevent formation of
estrogens and
dihydrotestosterone

Aromatase
inhibitor

Oral
capsules

[28]

5

Reduce conversion of
androgens to
estrogens

Aromatase
inhibitor

Oral
capsules

[29]

6

Effects of chrysin on
Urinary testosterone
levels

Aromatase
inhibitor

Oral, in
honey
and
propolis

[30]

7

Oral recurrent
aphthous ulcers

Antibacterial

Twice daily
for 1 week
total
250 mg/day
400 mg,
once
Twice daily
for 4 weeks,
total dose
625 mg/day
Three times
per day for 4
weeks, total
dose
300 mg/day
Three times
per day,
Week 1–2,
4–5, 7–8,
total dose
300 mg/day
1280 mg of
propolis,
and 20 g of
honey/day
for 3 weeks.
Not provided

Buccal
delivery
film

[31]

2. Clinical studies
Based on the results from PubMed query with “Chrysin” as the
keyword and “clinical study” as the search criterion, seven clinical
studies on chrysin have been conducted hereto as listed in Table 1 either
using pure chrysin or using a dietary supplements or herbal extracts
containing chrysin as the potential active ingredient. Among these
clinical studies, four studies aimed to investigate the effect of chrysin on
maintaining hormone homeostasis, one is for alleviating and preventing
chemotherapeutic drug irinotecan-induced diarrhea, and one is for
disposition study, and the other is for the treatment of ulcers using a
buccal delivery system. The results of these studies revealed that
chrysin’s efficacy as an aromatase inhibitor to prevent formation of es
trogens and dihydrotestosterone is moderate. However, chrysin showed
promising efficacy in preventing irinotecan-induced diarrhea without
affecting irinotecan’s therapeutically efficacy in cancer patients. Chrysin
prevents diarrhea through inducing intestinal UGT1A1, an enzyme that
can metabolize the toxic compound SN-38 in the intestine.
In these clinical studies, chrysin was administered through oral route
either in capsules as a pure compound or in an herbal extract. The
maximum dose was 625 mg/day for 4 weeks. Other than the disposition
study, chrysin in vivo exposure has not been reported in these studies.
Therefore, an intriguing and important question is whether the dosing
regimen affects chrysin’s efficacy. Pharmaceutical studies showed that
chrysin’s oral bioavailability is extremely poor (<1%) because of low
aqueous solubility and extensive metabolism (e.g., glucuronidation and
sulfonation), which will be discussed below. Therefore, in vivo efficacy
studies without pharmaceutical analysis may result in inaccurate
conclusion on chrysin. A suggestion for future clinical study is to
determine the maximal absorption dose of chrysin and in vivo chrysin
exposure and optimize the dosing regimen based on in vivo exposure. In
addition, administering chrysin in certain formulations (e.g., nano
particles) that can enhance its oral bioavailability should be considered
to evaluate its in vivo efficacy more appropriately.
The study using chrysin to alleviate irinotecan-induced GI toxicity is
fascinating. Although the systemic exposure is very poor, chrysin un
dergoes efficient enterohepatic recycling, resulting in repeated exposure
in the GI tract. Low oral bioavailability but repeated exposure in the GI
tract may be a benefit for chrysin when it is used to treat diseases or drug
induced toxicity in the GI tract because low systemic exposure but high
GI tract exposure could achieve local efficacy without or with limited off
target side effects. In other words, chrysin could be considered as a drug
that is formulated in a local delivery formulation for the lower GI tract.

[26,
27]

antiasthmatic [15], antidepressant [16], and anticancer effects [17], etc.
In addition, chrysin has also been tested as an adjuvant agent to improve
other drugs efficacy [18,19] or to alleviate toxicity induced by other
drugs [10,20–22]. Mechanism of action of these pharmacological effects
has also been investigated [2]. However, pharmaceutical studies showed
that oral bioavailability of chrysin is the biggest challenge in in vivo
efficacy studies. It was reported that chrysin’s absolute oral bioavail
ability is ~1% [23]. Poor bioavailability is because poor aqueous solu
bility and rapid metabolism in the GI tract and the liver as chrysin is a
good substrate of UGTs, a phase II metabolic enzymes catalyzing glu
curonidation and SULTs, phase II metabolic enzymes mediating sulfo
nation. In addition, chrysin glucuronide and sulfate are good substrates
of certain efflux transporters (e.g., MRP2, BCRP), which facilitate their
elimination through urine and feces.
Several review papers have been published focusing on chrysin’s
efficacy, molecular mechanism, clinical implications and figures/tables
illustrating chrysin’s pharmacological efficacy and molecular mecha
nism were available in these review articles [2,4,13,17,24]. This paper
reviews the pharmacokinetic and ADME studies of chrysin and discuss
2
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Table 2
Summary of chrysin pharmacokinetic studies in humans and animals.
#

Species

Dose (mg/
kg)

Route

Analytes

Tmax (hr)

Cmax

AUC

1

Human

400 mg

p.o. (capsule)

Chrysin

–

–

Sulfate

–

–

Chrysin
Glucuronide
Sulfate
Chrysin

4.00 ± 1.36
7.00 ± 1.15
6.50 ± 1.00
3.31 ± 3.12

0.01 ± 0.01 (μM)
0.16 ± 0.04 (μM)
0.13 ± 0.04 (μM)
0.02 ± 0.01(μM)

0.06 ± 0.03 (h
mL)
1.49 ± 0.49 (h
mL)
0.06 ± 0.03 (h
2.00 ± 0.82 (h
1.32 ± 0.42 (h
0.11 ± 0.08 (h

Glucuronide
Sulfate
Chrysin

1.81 ± 1.63
3.25 ± 3.57
1.00

[33]

2.00

3.54 ± 0.18

[33]

Chrysin
Glucuronide
Chrysin

5.20 ± 1.11
5.20 ± 1.09
5.50 ± 1.00

2.83 ± 3.03 (h μM)
2.62 ± 3.13 (h μM)
10.42 ± 0.96(h μg/
mL)
3.538 ± 0.78(h μg/
mL)
0.32 ± 0.05 (h μM)
10.4 ± 1.01(h μM)
0.36 ± 0.06 (h μM)

–
–
8.42 ± 0.32

Chrysin

0.02 ± 0.01(μM)
0.43 ± 0.67(μM)
0.99 ± 0.09 (μg/
mL)
0.42 ± 0.05 (μg/
mL)
0.02 ± 0.00 (μM)
0.76 ± 0.13 (μM)
0.02 ± 0.00 (μM)

9.17 ± 3.16
8.24 ± 1.80
11.0 ± 1.53

[37]

Glucuronide
Chrysin
Glucuronide
Chrysin
Glucuronide
Chrysin

6.25 ± 2.06
4.8 ± 1.09
6.20 ± 1.78
6.6 ± 1.37
5.60 ± 0.89
–

0.78 ± 0.13 (μM)
0.02 ± 0.00 (μM)
0.71 ± 0.13 (μM)
0.05 ± 0.00 (μM)
0.34 ± 0.13 (μM)
–

10.3 ± 0.73 (h μM)
0.34 ± 0.08 (h μM)
10.7 ± 2.69(h μM)
0.99 ± 0.25(h μM)
5.98 ± 2.47(h μM)
0.28 ± 0.05(h μg/mL)

8.53 ± 1.78
10.4 ± 2.67
8.45 ± 2.62
11.6 ± 2.37
9.11 ± 2.13
0.04 ± 0.01

Glucuronide

–

0.47 ± 0.18(h μg/mL)

0.4 ± 0.6

Sulfate

–

2.31 ± 1.07 (μg/
mL)
1.37 ± 0.47 (μg/
mL)
0.36 ± 0.12 (μg/
mL)
0.09 ± 0.02 (μg/
mL)
0.09 ± 0.02 (μg/
mL)
0.02 ± 0.01(μg/
mL)
0.02 ± 0.01 (μg/
mL)
0.04 ± 0.01 (μg/
mL)

0.424 ± 0.19(h μg/
mL)
2.70 ± 0.96 (h μg/
mL)
0.75 ± 0.24 (h μg/
mL)
0.39 ± 0.17 (h μg/
mL)
0.11 ± 0.08 (h μg/
mL)
0.08 ± 0.03 (h μg/
mL)
0.49 ± 0.07 (h μg/
mL)

0.2 ± 0.1

2

FVB mice

20

p.o. (oral suspending vehicle)

3

Bcrp(-/-)
mice

20

p.o. (oral suspending vehicle)

4

Wistar rats

10

5

Wistar rats

10

6

SD

30

p.o., Folate-conjugated
micelles
p.o. (formulation not
mentioned)
p.o. suspension

7

30

p.o. suspension in sodium
oleate

8

30

p.o. TW-80 nano-emulsion

9

30

sodium oleate nano-emulsion

2

i.v. (DMSO:PGE:ethanol:
Saline)

10

SD rats

11

SD rats

100

p.o. (corn oil)

Glucuronide

3.6 ± 0.6

12

Wistar Rats

0.23

p.o. in herbal extract

Chrysin

0.40 ± 0.15

13

Wistar rats

1.03

p.o. in herbal extract

Chrysin

0.61 ± 0.25

14

Wistar rats

1.12

p.o. in herbal extract

Chrysin

0.30 ± 0.10

15

SD

0.25

p.o. in herbal extract

Chrysin

0.25, 8

16

SD

0.54

p.o. in herbal extract

Chrysin

0.58 ± 0.11

3. Pharmacokinetics and oral bioavailability

T1/2 (hr)

Ref

μg/

4.6

[25]

μg/

–

μM)
μM)
μM)
μM)

–
–
–
–

[36]
[36]

[37]
[37]
[37]
[23]

3.0 ± 1.9

[23]

9.72 ± 3.16

[38]

4.79 ± 2.81

[39]

6.6 ± 0.8

[40]

4.51 ± 1.02

[35]

11.78 ± 1.38

[41]

intestine. In other words, a large proportion of chrysin dosed through
the oral route is not absorbed due to high apparent fecal elimination. If
low aqueous solubility is the major reason to cause poor oral bioavail
ability, approaches focusing on increasing aqueous solubility (e.g.,
nanoparticle formulation) should be developed to enhance chrysin’s
oral bioavailability.
Chrysin PK studies in mice and rats have also been conducted using
either pure chrysin or herbal extracts. Chrysin was administered orally
or intravenously in these preclinical PK studies. The dose in animal
studies ranged from 0.23 mg/kg to 100 mg/kg. The results showed that
when chrysin was administered as a pure compound, the Tmax was
2–6.6 h, while the Tmax was < 1.0 h when chrysin was administered in
herbal extracts. This is probably because the doses used as pure chrysin
were higher than the Maximum Absorbable Dose (MAD) [32], resulting
in chrysin being absorbed gradually, which delayed the Tmax. While
being present at a lower dose in herbal extracts, chrysin was absorbed
rapidly and completely in solution form in the intestine. This assumption
is also supported by the fact that when chrysin was administered in
formulations (e.g., folate-conjugated micelles) with better aqueous sol
ubility, the Tmax was shortened significantly [33]. The results also
revealed that the half-life of chrysin was relatively long at about 3–11 h
no matter either given as a pure compound or herbal extracts, which is
probably a result of enterohepatic recycling [34]. Double absorption
peaks at 0.25 h and 8 h reported in one of the studies listed in Table 2
confirmed the existence of recycling [35]. In animal studies, exposure (i.

3.1. Pharmacokinetic studies in animals and humans
A pharmacokinetic study in human volunteers has been conducted.
The results showed that when chrysin was administered to heathy vol
unteers at 400 mg, chrysin-sulfate was the major form detected in the
plasma with an AUC of 1490 ± 485 ng/mL⋅hr. Systemic exposure of
chrysin was about 20-fold lower with an AUC of 64 ± 33 ng/mL⋅hr. The
oral bioavailability of chrysin was estimated to be less than 1% by the
author in this study, which could probably explain why chrysin is very
potent in vitro but is not very promising in in vivo efficacy studies. This
study also reported that more than 90% of the chrysin was eliminated as
aglycone through the feces and the rest was eliminated as chrysin or
chrysin-glucuronide through urine [25]. High fecal elimination could be
because of either enterohepatic recycling or low aqueous solubility.
Chrysin participates enterohepatic recycling, which will be discussed
later, and the majority of chrysin could be excreted through the bile as
conjugate forms (e.g., glucuronide, sulfate), which can be hydrolyzed
back to chrysin in the terminal ileum or the colon by the intestine
microbiome. If this process is the major reason for poor oral bioavail
ability, approaches focusing on enterohepatic recycling and first
pass-metabolism (e.g., metabolic enzyme inhibitors) should be devel
oped in order to enhance chrysin oral bioavailability. On the other hand,
chrysin aqueous solubility is low, resulting in poor absorption in the
3
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e., Cmax, AUC) of chrysin conjugates was always higher than that of
chrysin in both mice and rats, indicating extensive metabolism as one of
the reasons for low systemic bioavailability.
In mouse PK study, both sulfate and glucuronide were detected, and
systemic exposure of chrysin-7-O-sulfate was higher than that of chrysin,
which is similar to the scenario in humans. In rats, glucuronide is the
major metabolite detected in the systemic circulation, probably because
the relative expression of UGTs is higher than those of SULTs in rats.
More pharmacokinetics and biopharmaceutical studies are needed to
verify whether rat is a good in vivo model to predict chrysin disposition
in humans. Another finding is that oxidative metabolites have never
been reported in in vivo PK studies although hydroxyl-chrysin was
detected as the metabolites when chrysin was incubated with micro
somes in in vitro studies (see metabolism section below).

Dihydroxy-2-phenyl-4H-1-benzopyran-4-one. Chrysin is a lipophilic
compound (Log P = 2.29) and has a low molecular weight
(MW=254.24). Chrysin’s aqueous solubility is 0.06 ± 0.1 mg/mL at pH
6.5, and 0.058 ± 0.04 mg/mL at pH 7.4 [48]. It was estimated that the
minimum aqueous solubility (MAS) of a medium permeable drug should
be higher than 0.05 μg/mL to achieve a good absorption when given at
1 mg/kg dose [49]. Chrysin’s permeability is medium and its solubility
is on this border if given at 1 mg/kg dose. However, in most of the an
imal and human studies, chrysin’s doses were higher than 1 mg/kg
(Tables 1 and 2), therefore, a large proportion of the dose was not
absorbable. This could partially explain why chrysin’s Tmax was longer
when given at higher doses (e.g., 10 mg/kg) than those at lower doses
(<1 mg/kg) in animal studies (Table 2). More studies are needed to
determine the impact of dosing regimens on chrysin’s pharmacokinetics
and pharmacodynamics.

3.2. Systemic and intestinal bioavailability

4.2. Absorption

Many studies indicated that the oral bioavailability of chrysin is
extremely poor [25,37]. Usually, only one digit of μM of chrysin can be
detected in the plasma regardless the doses when chrysin was admin
istered through oral route (Table 2). The absolute oral bioavailability (F
%) is < 1%. For example, in a PK study in adult male SD rats, chrysin F%
was 1% and the majority of the chrysin was detected in the plasma as the
glucuronide form [23]. Multiple factors limited chrysin’s oral bioavail
ability including low aqueous solubility, moderate permeability, and
rapid metabolism. Approaches intervening these factors can be devel
oped in order to improve chrysin oral bioavailability. Increasing water
solubility using formulations to enhance chrysin absorption have been
attempted. Example approaches include chrysin-folate conjugated mi
celles, chrysin-loaded PLGA-PEG nanoparticles, polymeric chrysin
nanocapsules, lipid-core nanocapsules [33,42–44]. The results from
these studies were encouraging because chrysin’s absorption can be
enhanced and in vivo exposure can be increased as showed in the PK
studies listed in Table 2 [33]. Another approach is to inhibit metabolism
for higher in vivo chrysin exposure. For example, it was reported that
when chrysin was administered together with sodium oleate, chrysin
metabolism was significantly inhibited and in vivo exposure (AUC) was
significantly increased in a PK study in SD rats [37].
Although chrysin’s systemic bioavailability is poor, its local
bioavailability in the intestine may not be necessarily poor. Due to low
solubility and poor absorption, a large proportion of the chrysin dosed
through the oral route may exceed its MAD. Although, this proportion of
chrysin cannot be absorbed into the systemic circulation, it may exert
certain pharmacological functions locally in the intestine, such as opti
mizing intestinal environment through interact with microbiome [45].
In addition, due to enterohepatic recycling, chrysin conjugates (i.e.,
chrysin-glucuronide, chrysin-sulfate) are secreted into the bile from the
hepatocytes and enter intestine, where the conjugates can be rapidly
hydrolyzed
to
release
chrysin
by
intestinal
microbial
beta-glucuronidases [46]. Thus, chrysin can be “reused” in the intestine,
resulting in enhanced its local bioavailability. It is not known how many
times can chrysin be reused in the intestine due to recycling, which
depends on the recycling efficient controlled by many factors including
metabolic rate, efflux efficient, and hydrolysis rate. It was estimated that
a bile acid molecule can be reused for about 20 times before being
eliminated through the body due to enterohepatic recycling [47]. For
chrysin, we expected that one molecule can be reused for “several” times
in the intestine. This feature renders chrysin as an ideal compound to
treat intestinal diseases with limited systemic impact.

Chrysin’s molecular weight is 254 and it has two hydrogen bond
donors (i.e., hydroxyl groups) and four hydrogen bond acceptors (i.e., 4
oxygens) in the structure. In addition, chrysin’s logP is 2.2. All these
features fit the Lipinski’s rule of five [50,51]. Theoretically, chrysin
should have a good absorption. In term of permeability, in the parallel
artificial membrane permeability (PAMPA) model, chrysin’s apical to
basolateral permeability is ~ 5 × 10− 6 cm/sec, suggesting that the
passive diffusion rate of chrysin is relatively fast. In the Caco-2 cell
culture model, the apparent absorption permeability of chrysin was
5–7 × 10− 6 cm/sec reported by different research groups [48,52]. These
findings revealed that chrysin intestinal absorption was moderate
because Caco-2 permeability at 10 × 10− 6 cm/sec range usually predicts
a > 75% of intestinal absorption in humans [53]. Bi-directional trans
port studies in the Caco-2 monolayer showed that the efflux ratio of
chrysin is ~0.87–2.0 at a concentration range of 5–25 μM [48,52]. It
seems like efflux transporter(s) is/are involved in chrysin’s absorption.
Our study showed that in the presence of Ko-143, a specific inhibitor of
BCRP, chrysin concentration in the basolateral side in a Caco-2 study
was slightly increased [54], suggesting Bcrp could be the involved
transporter. However, we further found that in Bcrp knockout (Bcrp
(-/-)) mice, in vivo exposure of chrysin and its metabolites was not
affected [54]. These findings revealed that chrysin mainly follows pas
sive diffusion transport mechanism and Bcrp might also be involved in
chrysin’s transport, but manipulation of BCRP does not significantly
increase chrysin’s absorption and bioavailability.
Chrysin’s intestinal absorption in in vivo study is affected by its low
aqueous solubility as mentioned above. Approaches focusing on
enhancing chrysin’s solubility have been attempted to improve chrysin’s
intestinal absorption. For example, it was reported that solubilizers,
such as cyclodextrin, can enhance both chrysin’s solubility and perme
ability in the Caco-2 cell culture model [55]. Another report showed that
chrysin in vivo absorption can be enhanced by certain formulations such
as nanoemulsion [37].
4.3. Distribution
The tissue distribution of chrysin has not been well studied. Effect on
gastric mucosa protection suggests that chrysin should have a sufficient
distribution in the stomach [56]. In addition, chrysin was reported to be
active in preventing cancers in different organs including mouth, colon,
liver, breast, kidney, prostate, and skin, suggesting that chrysin is
broadly distributed throughout these organs [57]. However, the pro
portion of chrysin distributed in these organs are unknown. It is ex
pected that chrysin has a relatively higher tissue distribution in the liver
and the GI tract due to efficient enterohepatic recycling. Clinical studies
have been conducted using chrysin to modulate UGTs in the GI tract to
prevent irinotecan-induced diarrhea. The results showed that systemic
exposure of SN-38 was not altered significantly when chrysin was

4. Biopharmaceutical mechanisms
4.1. Physical and chemical property
Chrysin (5,7-dihydroxyflavone) is a heterocyclic diphenol with two
hydroxyl group and its chemical name is 5,7-Dihydroxyflavone or 5,74
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combined with irinotecan [21]. In addition, diarrhea severity seems to
be reduced. These findings may reveal that UGT1A1, the enzyme cata
lyzing SN-38 metabolism, was only regulated in the intestine but not in
the liver by chrysin. If this hypothesis is correct, chrysin could have a
higher distribution in the GI tract to exert a better UGT1A1 regulation
when compared to the liver and other organs. Tissue bio-distribution
studies are highly expected to explain chrysin’s local efficacy in the GI
tract. This feature render chrysin a good locally bioavailable drug for the
treatment of local diseases without or with limited off-target side effects.
On the other hand, target delivery of chrysin should be paid special
attention to if the disease organ is not in the GI tract so that enough
chrysin can be delivered to that organ to exert its pharmacological
efficacy.

conclusion. Although sulfate is the major metabolite in the plasma, high
concentration of glucuronide was detected in the urine in humans [25].
In vivo exposure is a combination of both metabolism and elimination. It
was reported that chrysin-7-O-glucuronide is a good substrate of Bcrp
efflux transporter [60] and could be rapidly pumping out of the plasma,
resulting in low exposure level in the plasma.
4.4.3. Oxidation
When chrysin is incubated with CYP enzymes, it can be oxidized. It
was reported that chrysin was converted into tri-hydroxyl-flavone when
incubated with human liver microsomes and recombinant CYP isoforms
[65]. Additionally, chrysin was converted into 5,6,7-trihydroxyl-flavone
by CYP1A1, 1A2, 1B1.1, and 1B1.3. Metabolism rates ranged from 1 to 3
nmol/min/nmol CYP protein, which is a relatively low metabolic rate. In
addition, chrysin can also be converted into 5,7,4′ - trihydroxy-flavone
by CYP2A6 and CYP2A13 at an even lower rate [65].
Although in vitro study demonstrated that chrysin can be oxidized
into hydroxyl-chrysin, these oxidized metabolites have never been re
ported in in vivo studies. One of the possible reasons is that the con
centrations of these phase I metabolites are too low to be detected in
vivo, the other possible reason is that these hydroxyl-flavones can be
further conjugated into phase II metabolites. The other more probable
reason is that these oxidized metabolites may not exist in vivo because
chrysin can be rapidly conjugated into phase II metabolites and the
chance for chrysin to interact with CYPs is very low.

4.4. Metabolism
In vitro and in vivo studies showed that chrysin undergoes both
phase I and II metabolism. The metabolism pathway is illustrated in
Fig. 1. Chrysin-7-O-glucuronide and Chrysin-7-O-sulfate are the major
phase II metabolites mediated by UGTs or SULTs and 5,6,7-trihydroxylflavone and 5,7,4′ - trihydroxy-flavone are the major phase I metabolites
mediated by CYPs. Usually, liver is believed to be the major metabolic
organ due to high metabolic enzyme expression. For phase II meta
bolism, enzymes (e.g., UGTs and SULTs) are also highly expressed in the
other organs such as the GI tract and the kidney [58]. Therefore, other
than the liver, some other organs, especially the GI tract, can also
metabolize chrysin. Extensive metabolism in the GI tract and the liver is
one of the reasons to cause low oral bioavailability for chrysin.

4.4.4. Ring fission by microflora
In vitro and in vivo studies have demonstrated that ring fission
mediated by intestinal microflora is a common metabolism pathway for
many flavonoids [66]. Usually, the double bond between position 2 and
3 in a flavonoid structure is hydrogenated to form dihydroflavonoids,
followed by the middle ring being broken. The final products of ring
fission degradation are usually hydroxyphenylacetic/phenylpropionic
acid and phloroglucinol [67]. However, chrysin appeared to be resistant
to ring fission both in vivo and in vitro. In an early study, when chrysin
was incubated with intestinal microflora from male Wistar rats, unlike
other flavonoids, ring fission products were not detected [68]. Lack of
hydroxy groups in the B-ring was proposed as the rationale for ring
fission resistance. Human microflora metabolism study also suggested
that ring fission products of chrysin were barely detected [69].

4.4.1. Glucuronidation
Chrysin can be rapidly metabolized by UGTs to produce chrysin-7-Oglcuruonide as the major metabolites. Our studies demonstrated that
when incubated with liver and intestinal microsome, chrysin was
metabolized into chrysin-7-O-glucuronide at rates higher than those of
genistein, which is a well-known rapid metabolized isoflavone [59],
suggesting that chrysin glucuronidation is rapid. Other research groups
have found that chrysin-7-O-glucuronide is the major glucuronide in in
vitro and in vivo studies [23,60]. Multiple UGT isoforms are involved in
chrysin’s glucuronidation reaction when chrysin was incubated with
recombinant human UGT isoforms with the following order of potency:
UGT1A3 > 1A9 > 1A6 > 1A1 > 1A8 > 2B7 > 1A10 [61].

4.5. Elimination

4.4.2. Sulfonation
Sulfate is another major phase II metabolite. In vitro study showed
that when chrysin was incubated with Caco-2 cells, both chrysin-7-Oglucuronide and chrysin-7-O-sulfate were detected as the major me
tabolites [62]. Further studies showed that chrysin is a good substrate of
SULT1A3 and SULT1A1 and can be conjugated into chrysin-7-O-sulfate
[63].
Few studies have been done comparing chrysin glucuronidation in
different tissues such as in the intestine and the liver. Organ specific
metabolism may be important when using chrysin to treat diseases in
different organs. In additional to organ specificity, species difference of
chrysin metabolism is also important. It was reported that both chrysin7-O-glucuronide and chrysin-7-O-sulfate were detected in mice plasma
when chrysin was administered through oral gavage in animal PK
studies [54], while in rats, chrysin-7-O-glucuronide is the major
metabolite detected in the plasma as shown in Table 2. Human PK
studies results showed that chrysin-7-O-sulfate is the major metabolite
detected in the plasma and chrysin-7-O-glucuronide is mainly found in
the urine. These results revealed that chrysin disposition is
specie-dependent, thus specie-dependent metabolism studies using both
in vitro and in vivo models are suggested in future studies.
Some researchers think that sulfonation is the major metabolism
pathway for chrysin due to high sulfate concentration in the plasma in
humans [64]. We believe that more studies are needed to support such a

Clinical studies showed that chrysin was eliminated as glucuronide
through urine and chrysin appeared to be the major form eliminated
through feces [25]. When chrysin was administered to healthy volun
teers at 400 mg through the oral route, the total urine recoveries of
chrysin and chrysin-7-O-glucurnide were 1.0 ± 0.4 mg and
11.3 ± 3.0 mg, respectively. The total recovery in the urine was less
than 7%. Most of the dose appeared in feces and the total recovery in the
feces was more than 90% as the aglycone form. High aglycone elimi
nation could be because of enterohepatic recycling. In addition, since
chrysin’s aqueous solubility is poor, the insoluble and unabsorbed
portion of chrysin will be eliminated through feces directly. Rapid Tmax
(Table 2) when given at lower doses suggests the existence of unab
sorbed chrysin aglycone. Mechanism studies for chrysin elimination
have not been reported in preclinical studies. Further studies are needed
to reveal the mechanism of chrysin’s elimination.
4.6. Transporters facilitate disposition of chrysin
Caco-2 cell culture model, which is recognized by the FDA as a
standard model to study drug absorption, is believed to be a good cellbased model to identify transporters. In a transport study using the
Caco-2 model, the permeability of chrysin from basolateral to apical
(Pba) and from apical to basolateral (Pab) was slightly different with
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Fig. 2. The role of efflux transporters in the disposition of chrysin conjugates.

efflux ratio (Pba/Pab) close to 2, suggesting that efflux transporters might
be involved in chrysin’s transport [52]. However, this evidence is not
enough to conclude that chrysin is a substrate of certain efflux trans
porter(s) because: (1) efflux ratio is not high enough; and (2) efflux
could be because of metabolism-efflux interplay.
On the other hand, chrysin phase II conjugates are reported to be
good substrates of efflux transporters. For example, in the Caco-2
transport study, it was found that as much as 90% of chrysin conju
gates (i.e., chrysin-7-O-glucuronide, chrysin-7-O-sulfate) were detected
in the apical side when chrysin was loaded in the apical side [52]. In
testinal perfusion studies also demonstrated that when chrysin was
perfused through the rats intestine, high concentration of chrysin con
jugates were detected in the perfusate, suggesting that chrysin conju
gations were pumped back into the intestinal lumen [59]. Efficient
efflux of chrysin conjugates is another reason for its low intestinal ab
sorption and poor oral bioavailability. Efflux intervention could be a
direction to improve chrysin’s systemic and local bioavailability. Since
efflux transporters are expressed with different levels in different organs,
the role of efflux transporters in the elimination of chrysin conjugates
are different in these organs as illustrated in Fig. 2. So far, no evidence
supports the involvement of any uptake transporters in chrysin or its
conjugate transport.

chrysin-7-O-glucuronide secretion was significantly decreased, sug
gesting that glucuronide is a substrate of BCRP [60]. While in an animal
study, we found that the impact of Bcrp on chrysin and its conjugates is
limited as the PK parameters were not altered significantly in Bcrp
knockout mice compared to those in wild-type mice [54]. Current
findings suggested that chrysin conjugates are substrates of Bcrp, but the
impact of BCRP on in vivo chrysin and chrysin conjugates might be
minor. More PK studies are needed to evaluate the impact of BCRP on
chrysin in vivo exposure.
4.7.1. Multidrug resistance-associated proteins (MRPs)
MRPs are very common efflux transporters participating in the efflux
of many flavonoid conjugates, resulting in low systemic bioavailability
of the flavonoids. In an in vitro study using the Caco-2 cell culture
model, apical efflux of both chrysin glucuronide and sulfate were
decreased in the presence of MK-571, which is a specific MRP2 inhibitor,
suggesting that both glucuronide and sulfate are substrate of MPR2 [52].
Another in vitro study using HEK293 cell suggested that in the presence
of MK-571, the efflux of chrysin-7-O-sulfate was inhibited and the
intracellular level of sulfate was increased significantly [63]. These are
probably the only two evidences to show that MPR2 is involved in
chrysin conjugates efflux. Interestingly, it was reported that
chrysin-7-O-sulfates is a good substrate of MRP4 transporter. Evidence
to support this conclusion is that when MPR4 was knocked out in
HEK293 cells, secretion of chrysin-7-O-sulfate was decreased signifi
cantly and intracellular accumulation was increased significantly
(125–135%) [63]. MPR4 is located on the apical or basolateral side of
different organs (Fig. 2). For example, in the kidney and blood brain
barrier (BBB), MPR4 is expressed on the apical side, pumping
chrysin-sulfate into the urine in the kidney or blood in the brain. While
in the hepatocytes, MPR4 is located on the basolateral side transporting
chrysin-sulfate back into the blood from the hepatocytes [71]. MPR1
was
also
reported
to
be
a
transporter
facilitating
chrysin-7-O-glucuronide efflux in Hela cells [60].

4.7. Breast Cancer Resistance Protein (BCRP)
BCRP, which is highly expressed in many tissues including the in
testine, liver, and blood-brain barrier, is an essential efflux transporter
involved in many drug’s efflux. Other than normal tissues, BCRP is also
expressed in certain types of cancer cells and overexpression of BCRP is
proved to be an important reason for drug resistance in chemotherapy
[70]. In vitro studies using Caco-2 cell culture model showed that in the
presence of Ko-143, a specific chemical inhibitor for BCRP,
chrysing-7-O-sulfate efflux was significantly inhibited, while efflux of
chrysin-7-O-glucuronide was inhibited slightly, indicating that chrysin
sulfate, but not glucuronide, is a good substrate of BCRP while glucu
ronide is not (Fig. 2) [54]. However, RNA-mediated silencing results in
HeLa
cells
showed
that
when
BCRP
was
silenced,
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4.8. Enterohepatic recycling

Table 3
Transporters and metabolic enzymes inhibition (IC50, μM) by Chrysina.

Like many other flavonoids, chrysin undergoes efficient enter
ohepatic recycling after oral administration, where the aglycone is
absorbed in the small intestine and reaches to the liver through the
portal vein. Then, chrysin can be rapidly metabolized into glucuronide
and sulfate by hepatic UGTs and SULTs, followed by biliary secretion
facilitated by efflux transporters (e.g., BCRP, MPR2). The secreted
conjugates (e.g., chrysin-7-O-glucuronide and chrysin-7-O-sulfate) will
reach the colon through the small intestine to meet with intestinal
microbiome and can be efficiently hydrolyzed back into chrysin by
microbial beta-glucuronidases (GUS). Then, the newly released chrysin
can be absorbed and reach the liver to form a recycle, resulting in
multiple absorption peaks and long half-life in PK profile. Due to recy
cling, chrysin will be presented in the colon and terminal ileum multiple
times like a shuttle before being directly eliminated through feces or
urine via systemic circulation. In PK studies in rats, chrysin showed two
absorption peaks at around 2 and 5–10 hrs with a half-life at 4–9 h re
ported by different research groups [35,38]. PK studies in mice also
found double absorption peaks at a similar time [54]. In human, there
are three absorption peaks at around 2, 6, and 24 h. All these PK studies
in different species revealed that chrysin participates in recycling.
Although recycling was observed in chrysin’s PK studies, the recy
cling mechanism is not entirely understood. In an in situ study in rats, we
have found that when chrysin was perfused through the intestine, about
1/3 of chrysin was detected in the portal vein as glucuronide form [59].
In addition, when chrysin-7-O-glucuronide was infused through the
portal vein, the majority amount of chrysin-7-O-glucuronide was
detected in the bile, indicating that hepatocytes can uptake
chrysin-7-O-glucuronide, which is then secreted into the bile and then to
the intestine. These findings suggest that chrysin can also be metabo
lized in the GI tract and enter the liver through portal vein as the
glucuronide form, followed by secretion from the bile to participate in
recycling. This is different from traditional enterohepatic recycling, in
which aglycone is absorbed and metabolized in the liver. More studies
are expected to explain and further investigate this observation.

Transporters and enzymes

Chrysin

Chrysin-glucuronide

Chrysin-sulfate

OATP1A2
OATP1B1
OATP1B3
OATP2B1
BCRP
MPR2
CYP2C9
CYP2C19

>100
>100
>100
4.8
0.4
>100
3.2
4.6

24.1
4.4
14.3
0.3
19.8
11.2
>100
>100

18.3
0.8
1.7
0.5
0.6
>100
2.7
>100

a

Data from reference [78].

4.9.2. BCRP inhibition
Chrysin is a strong BCRP inhibitor as demonstrated in in vitro studies
using cell lines [77]. A recent comprehensive study showed that chrysin
BCRP inhibition IC50 was 0.4 μM [78]. Molecular docking analysis
showed that chrysin binds with BCRP through Pi-Pi stacked interaction
with Phe 439 of BCRP or Pi-Alkyl interactions with Val546 of BCRP,
instead of conventional hydrogen bonds [79]. However, some in vivo
studies showed that chrysin played a minor role in substrate efflux [80,
81]. Solubility could be one of the primary reasons to causing incon
sistency between in vitro and in vivo studies when evaluating chrysin’s
BCRP inhibition. When chrysin was administered through a solid
dispersion formulation, which significantly improves chrysin’s solubil
ity, oral bioavailability of BCRP substrates (e.g., topotecan, doxorubicin,
temozolomide, mitoxantrone) were significantly enhanced [79,82].
Since the water solubility of chrysin is low, in vivo achievable concen
trations of chrysin should be taken into consideration in future pre
clinical and clinical studies.
4.9.3. Other interactions
In vitro studies demonstrated that chrysin and chrysin conjugates
also inhibit CYPs [83,84]and transporters including OATPs, MRP2 [81,
85] as shown in Table 3.
5. Remarks

4.9. Interaction with the host

Chrysin is a dietary component possessing multiple beneficial ac
tivities. Clinical trials using chrysin as an adjuvant agent to treat several
diseases (e.g. hormone homeostasis, drug-induced GI toxicity) have
been conducted and the results turned out to be very interesting. Bio
pharmaceutical studies showed that chrysin absorption is moderate due
to its low solubility and moderate permeability. Low oral bioavailability
is the challenge for developing chrysin as a therapeutic drug. Multiple
metabolic enzymes (e.g., UGTs, SULTs, CYPs) and transporters (e.g.,
BCRP, MRP2/MRP4) are involved in chrysin’s disposition, which can be
further studied as potential targets to enhance chrysin’s bioavailability.
Further studies on tissue and species variation in ADME of chrysin would
be helpful for developing chrysin as a therapeutic agent using animal
models and in clinical studies.

4.9.1. UGT induction
Many studies have demonstrated that chrysin could induce UGT1A1
in different cell lines including Caco-2 and HepG2 cells with different
sensitivity. For example, in an in vitro study, it was demonstrated that
when Caco-2 cells were exposed to 50 μM of chrysin, glucuronidation
function increased 3.8-fold in the intact cells or 14-fold in cell lysate
[72]. Further studies showed that in Caco-2 cells, chrysin (25 μM)
significantly induced UGT1A1 expression as shown by Northern blot
analysis [73]. In addition, in vitro studies using HepG cells demon
strated that chrysin induced UGT1A1 at mRNA, protein, and functional
levels [74]. Mechanism studies revealed that chrysin induces UGT1A1 in
a MEK-1-dependent manner involving the Ah receptor [75].
As abovementioned, chrysin is a dietary component mainly in honey
and is relatively safe. Therefore, it has been suggested to use chrysin as a
UGT1A1 inducer to enhance detoxification via glucuronidation or to
treat inheritance diseases such as Gilbert’s syndrome. Clinical studies
have been conducted using chrysin to alleviate irinotecan-induced in
testinal injury and diarrhea, where intestinal UGT1A1 is expected to be
induced to enhance intestinal glucuronidation of SN-38, the toxic
compound causing local damage. The results turned out to be promising
[21]. However, chrysin is also a UGT1A1 substrate. It has been sug
gested that the metabolic stability of chrysin would limit its ability to
induce UGT1A1 in vivo [76]. Future studies should focus on dynamic
changes of chrysin concentration when using chrysin as a UGT1A1
inducer. Additionally, GI tract is theoretically the best organ for UGT
induction using chrysin because its oral bioavailability is poor and in
vivo exposure is usually low.
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